+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07658638

Safety and Pharmacokinetics Study of IV TESP-0401 in Healthy Adults with Single and Multiple Doses

Led by Tes Pharma S.r.l. · Updated on 2026-09-14

68

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, tolerability, and how the body processes TESP-0401 in healthy adult volunteers. This randomized, placebo-controlled study aims to understand these factors after both single and multiple intravenous doses of the drug. The study is designed as a Phase 1 trial to carefully assess how TESP-0401 behaves in the body and to monitor any adverse effects in healthy participants. Participants will receive TESP-0401 or a placebo through intravenous infusion over 60 minutes while fasting. The study includes two parts Part A with single ascending doses and Part B with multiple ascending doses administered once daily for seven days. Each participant will be assigned randomly to either the experimental or placebo group in a parallel design. During the study, participants will be closely monitored for safety through clinical lab tests, vital signs, ECG readings, and physical exams up to eight days after the last dose. Researchers will measure drug concentrations, how quickly it reaches peak levels, clearance rates, half-life, volume of distribution, and drug accumulation over up to nine days. The entire participation includes confinement at the clinical research unit and adherence to study restrictions to ensure accurate monitoring of safety and pharmacokinetics.

CONDITIONS

Brief Title

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TESP-0401 in Healthy Participants

Research Team

J

Jennifer Martin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here